Jpmorgan Chase & CO Blueprint Medicines Corp Call Options Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BPMC
# of Institutions
401Shares Held
67.4MCall Options Held
1.12MPut Options Held
1.67M-
Black Rock Inc. New York, NY6.65MShares$861 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.42MShares$831 Million0.01% of portfolio
-
Pentwater Capital Management LP Naples, FL3.9MShares$505 Million3.34% of portfolio
-
State Street Corp Boston, MA2.23MShares$289 Million0.01% of portfolio
-
Ubs Group Ag2.17MShares$281 Million0.05% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $7.73B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...